Expert Commentary

In young hysterectomized women, does unopposed estrogen therapy increase overall survival?

Author and Disclosure Information

Yes. Between 2002 and 2011, a minimum of 18,601 and as many as 91,610 excess deaths occurred among hysterectomized US women aged 50 to 59 years, according to this analysis. These deaths were attributed to the avoidance of estrogen therapy (ET) in the years following publication of the initial findings of the Women’s Health Initiative (WHI).1

Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health. 2013;103(9):1583–1588.


 

References

During the 1990s, more than 90% of hysterectomized women aged 50 to 59 years used ET following the procedure. When the initial findings of the WHI were published in 2002, they prompted many women to refuse or discontinue ET—despite the fact that the initial findings concerned the use of estrogen and progestin in combination in women with an intact uterus. Today, only some 30% of women use ET after hysterectomy.

When findings from the WHI estrogen-only arm were eventually published, they revealed that ET reduces mortality among women 50 to 59 years old, compared with placebo. Although most of the reduction in mortality relates to fewer deaths from coronary heart disease, a decline in deaths from breast cancer also was seen.2,3

Sarrel and colleagues calculated the excess mortality among US women aged 50 to 59 that could have been prevented by ET during the decade from 2002 through 2011. Their estimates ranged from approximately 19,000 deaths to as many as 92,000 deaths.

By calling attention to the negative health consequences of estrogen avoidance in young hysterectomized women, Sarrel and colleagues have performed a valuable public service.

Plethora of WHI data may have contributed to confusion

The WHI clinical trials have produced numerous analyses in various subsets of women. The sheer volume of data may be daunting in some cases, and likely has led to a failure to distinguish between estrogen-only and estrogen-progestin therapy, which have very different safety profiles.

Further, some clinicians and many patients have overlooked the fact that the risk-benefit profile of hormone therapy (both estrogen-only and estrogen-progestin therapy) is more favorable in younger, recently menopausal women than it is in older women.

I encounter evidence of this unwarranted fear of ET in my practice, with highly symptomatic, recently menopausal women who are appropriate candidates for hormone therapy electing to refuse the most effective treatment for menopausal symptoms.

Of course, hormone therapy, like all medications, has risks as well as benefits. For example, oral ET increases the risk of venous thrombosis and stroke, and long-term use of estrogen-progestin therapy increases the risk of breast cancer. However, the overblown fears of estrogen therapy have caused many appropriate candidates to miss out on symptom relief, prevention of osteoporosis, and treatment of symptomatic genital atrophy.

What this evidence means for practice
This provocative report demonstrates that wholesale avoidance of hormone therapy can have important negative public health consequence.
--Andrew M. Kaunitz, MD

We want to hear from you! Tell us what you think.

Recommended Reading

Is there a link between impaired mobility and urinary incontinence in elderly, community-dwelling women?
MDedge ObGyn
Studies speak volumes about brain changes and cognition in women
MDedge ObGyn
Switching nonadherent to denosumab improved bone density
MDedge ObGyn
What is the gynecologist’s role in the care of BRCA previvors?
MDedge ObGyn
Female hair loss differs by age
MDedge ObGyn
Follow-up bone mineral density didn’t sharpen fracture risk assessment
MDedge ObGyn
Your postmenopausal patient reports a history of migraine
MDedge ObGyn
No weight gain or sexual dysfunction with first nonhormonal treatment for hot flashes
MDedge ObGyn
New option for treating menopausal vasomotor symptoms receives FDA approval
MDedge ObGyn
Ospemifene for dyspareunia in postmenopausal women is well tolerated
MDedge ObGyn

Related Articles